Summary The present study describes a comparison of two potent immunotoxins which utilise an identical targeting component, a monoclonal antibody (SEN7) specific for small cell lung cancer (SCLC), conjugated to two different effector components, blocked ricin (bR) and Pseudomonas exotoxin A (PE). SEN7 recognises a novel epitope on the neural cell adhesion molecule (NCAM) which is highly associated with SCLC. The immunotoxins SEN7-PE and SEN7-bR were selectively and potently active against a number of SCLC cell lines, of both classic and variant morphologies, inhibiting the incorporation of [3H]leucine with IC50 values ranging between 22 pM and 85 pM and between 7 pM and 62 pM for SEN7-PE and SEN7-bR respectively. Intoxication by both immunotoxins proceeded rapidly following short 2 h lag phases; the initial rates of protein synthesis inhibition occurred with t50 values of 6.5 h for SEN7-PE and 5.5 h for SEN7-bR. Monensin drastically enhanced the cytotoxic activity of the weakly active SEN7-ricin A-chain by 2,100-fold and of SEN7-bR by 80-fold but had no effect on SEN7-PE. In limiting dilution assays, four and more than 4.5 logs of clonogenic SW2 tumour cells were selectively eliminated from the cultures during continuous exposure to the immunotoxins SEN7-PE and SEN7-bR respectively, while antigen-negative cells required up to 1,000-fold more drug for a similar cell kill. SW2 cells surviving SEN7-bR treatment in the cultures did not express NCAM and consequently were not selectively killed by SEN7 immunotoxins. SW2 cells surviving continuous exposure to SEN7-PE showed no alteration in NCAM expression but were more resistant to intoxication mediated by PE. These cells were still sensitive to SEN7-bR.
Small cell lung cancer (SCLC) is one of the most fatal malignancies and presents as disseminated disease in over 65% of cases. Despite the initial sensitivity of SCLC to radiation and chemotherapy, novel treatment modalities appear necessary since the emergence of a drug-resistant phenotype is the primary reason for failure of conventional therapy to cure this disease (Carney & de Lei, 1988) .
The use of immunotoxins as adjuncts to conventional chemotherapeutic drugs has received considerable attention because these agents have mechanisms of action distinct from conventional chemotherapy and those cancer cells that are naturally resistant or acquire resistance to chemotherapeutic drugs will not be cross-resistant to toxin-based therapies (FitzGerald et al., 1987) . The plant toxin ricin and the bacterial toxin Pseudomonas exotoxin A (PE) act by arresting the synthesis of proteins in eukaryotic cells employing different mechanisms of action. The A-chain of ricin has an irreversible N-glycosidase activity and acts on the 60S ribosomal subunit (Endo et al., 1987) . The catalytic domain of PE has ADP-ribosyl transferase activity which is essentially irreversible under physiological conditions and acts on the elongation factor 2 (Iglewski et al., 1977) . The process of intoxication is promoted by ubiquitous expression of cellsurface receptors, terminal galactosyl residues for ricin (Blakey & Thorpe, 1988) and the M2-macroglobulin receptor for PE (Kounnas et al., 1992) . To increase their selectivity, these toxins must be modified so that interactions through the natural receptors are diminished or abolished. Blocked ricin (bR) is a derivative in which the galactose binding sites of the B-chain are blocked by chemical modification resulting in a 3,500-fold lower binding affinity (Lambert et al., 1991a,b) . With PE modification occurs most efficiently when the MAb is coupled to domain I via a thioether linkage which sterically blocks its cell-binding activity (Morgan et al., 1990; FitzGerald et al., 1990) . Both bR and PE blocked by a thioether linkage have intact translocation and catalytic domains. If a target antigen is internalised by the cell modification can be accomplished through removal of the B-chain of ricin (Blakey & Thorpe, 1988) or through genetically deleting domain I of PE (Pastan & FitzGerald, 1991 (Wawrzynczak et al., 1990; Derbyshire et al., 1992a; Zangemeister-Wittke et al., 1993a,b) as well as in the clinic (Lynch et al., 1993) .
MAbs belonging to the major cluster 1 were found to be directed against the neural cell adhesion molecule (NCAM) (Souhami et al., 1991) , a member of the immunoglobulin superfamily which is expressed with high frequency on brain tumours, neuroblastomas, Wilms' tumour and SCLC (Patel et al., 1990; Moolenaar et al., 1990; Carbone et al., 1991) . Multiple NCAM isoforms have been found representing a combination of cell type and developmentally stage-specific splicing and sialylation (Rothbard et al., 1982; Rougon et al., 1982) . The MAb SEN7, a previously described mouse IgGI (Waibel et al., 1993) , recognises an epitope on NCAM that is homogeneously expressed on all SCLC cells. In contrast to previously described cluster 1 MAbs, SEN7 does not react with lymphoid tissue and peripheral blood lymphocytes and thus might prove a promising candidate for the selective delivery of highly cytotoxic agents to SCLC.
In the present study the NCAM-specific MAb SEN7 was evaluated for its potential to make potent and selective immunotoxins against SCLC. Because in previous studies ricin A-chain immunotoxins directed against NCAM on SCLC could not prove potent cytotoxic agents (Wawrzynczak et al., 1991; Derbyshire et al., 1992b) , the whole toxin molecules bR and PE were used for immunotoxin preparations. In a series of tissue culture experiments the cytotoxic properties of SEN7-bR and of SEN7-PE were examined in detail. Technologies, UK) containing 4 mM L-glutamine supplemented with 10% fetal calf serum at 37°C in a humidified atmosphere. Cell lines were maintained in exponential growth as asynchronous cultures and were found to be free of mycoplasma infection.
Monoclonal antibodies and immunotoxins
The monoclonal antibody (MAb) SEN7, a mouse IgG1 recognising an epitope on the neural cell adhesion molecule (NCAM) (Waibel et al., 1993) , and the isotype-matched control MAb SJ25-Cl (anti-CD19; Sigma, St Louis, MO, USA) were used for immunotoxin preparations. The isotypematched control immunotoxin anti-B4-blocked ricin (bR) (anti-CD19; Shah et al., 1993) was supplied by Immunogen (Cambridge, MA, USA). The mouse IgGl SEN36, recognising a different cluster 1 (NCAM) epitope (Wawrzynczak et al., 1991) , was used as control for immunofluorescence analyses. The mouse IgGI SEN31, recognising the cluster 5a antigen (Zangemeister-Wittke et al., 1993b) , was used as control in the internalisation assay. MAbs SEN7, SEN36 and SEN31 were purified from hybridoma supernatants by protein A affinity chromatography in 0.1 M Tris-HCI buffer pH 8.5 containing 3 M sodium chloride. The antibodies were eluted with 50mM sodium phosphate buffer (pH 6.0) containing 150 mM sodium chloride, then subjected to ionexchange chromatography on Mono S HR5/5 (Pharmacia, Sweden) and eluted with a 0-500mM gradient of sodium chloride in a buffer of 50mM sodium phosphate. Ricin Achain (Inland Laboratories, Austin, TX, USA) was attached to SEN7 and SJ25-C1 via disulphide bonds according to the procedure described by Cumber et al. (1985) . Briefly, MAbs were reacted with N-succinimidyl 3-(pyridyldithio) propionate (SPDP) (Pierce, Rockford, IL, USA) to introduce an average of two groups per antibody. Derivatised MAbs were reacted overnight with a 2.5-fold molar excess of freshly reduced ricin A-chain and the mixtures were applied to a column of Sephacryl S200HR (Pharmacia, Sweden).
SEN7-blocked ricin (bR) was prepared essentially as previously described (Lambert et al., 1991b) . Briefly, purified SEN7 in PBS containing 1 mM EDTA was reacted with a 5-fold molar excess of succinimidyl 4-(N-maleimidomethyl)-cyclohexane carboxylate (SMCC) (Pierce) and incubated at 30°C for 30 min. The antibody was separated from the unreacted cross-linker on a Fast Desalting HR10/10 column (Pharmacia, Sweden). Blocked ricin (bR) was reduced in PBS (pH 6.8) containing 3 mM dithiothreitol (DTT) (Sigma) and 3 mM EDTA at 4°C for 20 h. DTT was separated from bR on a Fast Desalting HR10/10 column equilibrated with 5 mm sodium acetate pH 4.7. Modified SEN7 in PBS was mixed with a 3-fold molar excess of freshly reduced bR and the reaction mixture was allowed to stand overnight at 4°C. SEN7-bR was separated from unconjugated antibody and unconjugated bR by ion-exchange chromatography on a Mono S HR5/5 column in 50 mM sodium acetate (pH 5.0) followed by immunoaffinity chromatography on a monoclonal anti-ricin column in 100 mM phosphate (pH 7.0). SEN7-bR was eluted with 100 mM glycine-HCI (pH 2.7) and neutralised with sodium phosphate.
For the preparation of SEN7-Pseudomonas exotoxin A (PE) and SJ25-C1-PE, purified MAbs at 5-10mg ml-' were mixed with a 3-fold molar excess of 2-iminothiolane hydrochloride in 100 mM sodium phosphate (pH 8. (Pharmacia, Sweden) . The resulting immunotoxin preparations, which consisted predominantly of 1:1 conjugates of antibodies and toxins as determined by SDS-PAGE under non-reducing conditions (Fast Electrophoresis System, Pharmacia, Sweden), were pooled and stored frozen at -70C in PBS.
Antibody internalisation assay The internalisation capacity of SEN7 was evaluated by an immunofluorescence cytochemical assay designed to visualise internalized antibody without interference from surfacebound antibody as described by Chang et al. (1992) with modifications. Approximately 5 x I05 SW2 cells in 1.5 ml microfuge tubes were washed in cold PBS-1% BSA followed by incubation with 0.1 gM SEN7 or SEN31 control antibody at 4°C for 1 h. The cell suspensions were warmed to 37°C for 45 min to allow the surface-bound antibody to internalise into the cells. After washing in PBS.-1% BSA, the cells were incubated with an acid buffer (pH 2.8) containing 0.1 M sodium chloride and 50 mM glycine-HCl at 0'C for 15 min, then washed in PBS-1% BSA, and incubated with PBS containing 3 mg ml-' normal goat '-globulin and 0.1% saponin for 15 min. The cells were incubated for 1 h with rhodamine-labelled goat anti-mouse F(ab')2 IgG fragments (Jackson ImmunoRes. Lab., PA, USA) in 3 mg ml-' normal goat globulin-0. 1% saponin-PBS, washed and fixed again with 3.7% formaldehyde for 10min and finally washed in PBS. Cytospin preparations of 105 cells were mounted in Vectashield medium (Vector Laboratories, Burlingame, CA, USA) and analysed using a confocal laser microscope (LMS, Zeiss, Germany).
FITC labelling of MAbs
The MAbs SEN7 and SEN36 were dialysed against 0.1 M borate buffer pH9.0, and allowed to react with a 15-fold (SEN7) or 25-fold (SEN36) molar excess of fluorescein isothiocyanate (FITC) (Fluka, Buchs, Switzerland) dissolved in dimethylformamide for 6h at 4°C. The 
Statistics
All data shown represent the mean of at least three independent determinations. The Student's t-test was used to determine the significance of differences in the cell binding activities. P-values <0.05 were taken as statistically significant.
Results
Internalisation of SEN7 To determine whether or not SEN7 was rapidly internalised, SW2 cells were subjected to an internalisation assay using SEN7 and a positive control antibody, SEN31, which recognises the cluster 5a antigen on SCLC cells.
After 45 min at 0°C and 37°C, all of the MAb SEN7 remained on the cell surface (Figure la and b) , whereas large amounts of the control MAb SEN31 were detected within the cells following incubation at 37°C (Figure lc ). This indicates that very little if any of the target epitope internalised upon exposure to SEN7.
Cell-binding activities of immunotoxins
In a competitive binding assay the ability of the immunotoxins SEN7-PE, SEN7-bR and SEN7-ricin A-chain to inhibit the binding of FITC-labelled SEN7 to SW2 cells was examined and compared directly with that of unmodified SEN7.
As shown in Figure 2 , binding of the labelled antibody was half-maximally inhibited by 5 nM SEN7. The immunotoxins & cif all Figure 1 Internalisation of cell surface-bound MAb SEN7 by SW2 cells. Cells were incubated for 45 min at O'C a, or at 37'C b, in the presence of saturating amounts of SEN7. Following fixation and permeabilisation, cell-associated antibody was visualised by staining with rhodamine-labelled goat anti-mouse F(ab')2 IgG fragments either directly (a', b') or after stripping the cell surface with an acid buffer (a", b"). In a positive control experiment cells were incubated at 37°C with the cluster 5a-specific MAb SEN31 and internalised antibody is shown following treatment of cells without (c') and with (c") acid buffer. Photographs were taken from cytospin preparations using a Zeiss LMS confocal laser microscope.
inhibited the binding of FITC-labelled SEN7 to 50% at concentrations of 9nM (SEN7-PE), 16nM (SEN7-bR) and 8 nM (SEN7-ricin A-chain). This reflects a 2-3-fold loss compared with the unmodified antibody.
Cytotoxic activities of immunotoxins
The cytotoxic activities of the immunotoxins SEN7-PE, SEN7-bR and SEN7-ricin A-chain were determined against a panel of antigen-positive SCLC cell lines and antigennegative control cell lines in tissue culture during a 24 h exposure in [3H]leucine incorporation assays (Table Ia) . The cytotoxic activitites of irrelevant (anti-CDl9) control immunotoxins and of the corresponding unconjugated toxins were determined in parallel (Table lb) .
SEN7-PE and SEN7-bR were potently and selectively toxic to the antigen-positive cell lines, inhibiting protein synthesis by 50% compared with untreated control cells at concentrations (IC.0) ranging between 22 pM and 85 pM and between 7.3 pM and 62 pM respectively. The activity against the antigen-negative cell lines LXI and U1752 was more than 400-to 800-fold lower, as was the unspecific cytotoxic effect (2.2 ± 1.1) x 10-1" (7.9 ± 2.7) x 10-12 (2.2 ± 0.4) x 10-8 OHI (5.0 ± 1.8) x 10-1" (3.1 ± 2.0) x 10-"1 (3.3 ± 0.7) x 10-8 OH3 (2.6 ± 2.1) x 10-" (1.2 ± 0.3) x 10-" (1.6 ± 1.2) x 10-8 H60 (4.0 ± 1.4) x 10-" (3.8 ± 0.6) x 10-" (5.1 ± 2.3) x 10-8 N417 (8.5 ± 3.1) x 10-11 (6.2 ± 2.6) x 10-11 > 10-8 DC571.38 (5.4 ± 2.1) x 10-"1 (7.3 ± 2.2) x 10-12 > 10-8 LX1b (9.3 ± 3.0) x 10-9 (4.2 ± 1.9) x 10-9
U1752b,c (6.4 ± 2.8) x 10 9 (2.6 ± 0.9) x 10 9 > 10-8 aMean ± s.d. from three independent experiments in terms of toxin concentration. bAntigen-negative cell line. cSquamous lung cancer cell line. (3.9 ± 2.2) x 10-9 (2.1 ± 0.9) x 10-9 (3.3 ± 0.5) x 10-8 (5.0 ± 2.2) x 10-10 (9.1 ± 2.5) x 10-10 (5.7 ± 2.6) x 10-8 OHI (8.5 ± 3.6) x 10-9 (2.7 ± 1.6) x 10-9 (2.1 ± 0.9) x 10-8 (1.1 ± 0.4) x 10-9 (2.5 ± 1.8) x 10-9 (4.3 ± 1.7) x 10-8 OH3 (5.9 ± 2.7) x 10-9 (9.5 ± 4.3) x 10-10 (1.7 ± 1.0) x 10-8 (7.2 ± 3.1) x 10-10 (1.3 ± 0.8) x 10-9 (5.2 ± 2.2) x 10-8 N417 ND
(1.4 ± 0.8) x 10-9 > 10-8 ND ND ND DC571.38 ND ND ND (5.2 ± 2.1) x 10-10 (7.5 ± 2.6) x 10-10 > 10-8 LXlb (7.0 ± 3.4) x 10-9 (1.9 ± 1.1) x 10-9 > 10-7 (6.9 ± 2.0) x 10-10 (2.8 ± 1.3) x 10-9 > l0o-U1752bc ND ND ND (3.8 ± 1.9) x 10-10 (4.6 ± 2.1) x 10-9 were only weakly active against all cell lines tested (IC50> 1O nM), indicating that SEN7 is not an efficient carrier of A-chain toxicity in the absence of internalisation and translocation mediated by the toxin.
Specificity of action of immunotoxins
The specificity of action of SEN7-PE, SEN7-bR and SEN7-ricin A-chain was examined using the SW2 cell line in tissue culture. Figure 3 shows the representative concentration-activity curves obtained in Table Ta ). In contrast, blocking of the binding sites with an excess amount of SEN7 reduced the cytotoxic effects of SEN7-PE and SEN7-bR by about 500-and 200-fold respectively.
Potentiation of immunotoxins
The potentiating agents monensin, ammonium chloride and chloroquine were tested for their abilities to enhance the cytotoxic activity of SEN7-PE, SEN7-bR and SEN7-ricin A-chain against SW2 cells and antigen-negative LXI control cells in tissue culture. Control (anti-CD19) immunotoxins were tested in parallel. Potentiators were used at concentrations which inhibited [3H]leucine incorporation in the assays less than 15%.
Ammonium chloride and chloroquine had no potentiating effect on either of the immunotoxins (data not shown). As shown in Table II monensin at a concentration of 80nM drastically enhanced the antigen-specific activity of the ricin immunoconjugates against SW2 cells. SEN7-ricin A-chain was enhanced by 2,100-fold and SEN7-bR by 80-fold. This potentiating effect of monensin was not entirely selective because the activity against LXI cells was slightly enhanced: 27-(SEN7-bR) or 8-fold (SEN7-ricin A-chain). In addition, unconjugated bR and ricin A-chain were each enhanced by and incubated for 21 days under tissue culture conditions. Estimates of surviving clonogenic cells were made by a limiting dilution assay. The killing efficiencies of the immunotoxins were judged from the reduction in the number of colonies compared with the untreated control cultures. As shown in Figure 5 , SEN7-PE reduced the surviving fraction of clonogenic SW2 cells by more than 4 logs at a concentration (1 nM) which eliminated less than 0.5 log of clonogenic LX1 cells. SEN7-bR was even more potent and killed up to 5 logs of SW2 cells at a concentration of 0.7 nM, while LXI cells required up to 1,000-fold more drug for a similar cell kill.
NCAM expression and susceptibility to SEN7 immunotoxins of SW2 cells pre-exposed in limiting dilution assays The presence of the target epitope recognised by SEN7 was quantitated by FACS analyses of SW2 cells which had survived continuous exposure to either 1 nM SEN7-PE or 0.1 nM SEN7-bR in limiting dilution assays. Staining with SEN36, which recognises a different epitope on NCAM, was done for comparison. In addition, the susceptibility of the cells to the immunotoxins and to unconjugated PE or bR was examined in [3H]leucine incorporation assays. Non-pretreated SW2 cells were used as controls.
As shown in Table III (1.5 ± 0.4) x 10-11 (7.5 ± 2.3) x 10-12 (5.3 ± 2.0) x 10-10 (8.4 ± 2.9) x 10-10 SEN7-PE 333/371
(1.9 ± 1.1) x 10-9 (8.2 ± 2.7) x 10-12 (4.9 ± 2.2) x 10-9 (7.4 ± 2.1) x 10-'°S EN7-bR 98/109 (5.3 ± 2.8) x 10-9 (8.5 ± 1.9) x 10-10 (5.9 ± 2.4) x 1010 (9.0 ± 3. (Lambert et al., 1991a,b) . Native PE was conjugated to SEN7 via a thioether linkage (Morgan et al., 1990; FitzGerald et al., 1990 (Olsnes et al., 1989; Sandvig et al., 1991) , translocation of PE seems to be confined to the endoplasmic reticulum (FitzGerald & Pastan, 1992) . In view of recent progress in enhancing the potentiating effect of monensin in vivo (Hertler et al., 1989; Griffin et to SEN7-bR but were more than 10-fold less susceptible to intoxication by PE. The different mechanisms of resistance which were observed following pretreatment with the immunotoxins coincide with the different mechanisms of action of the corresponding catalytic domains. Ricin has an N-glycosidase activity which is not reversible (Endo et al., 1987) . Similarly, the ADP-ribosyl transferase activity of PE is essentially irreversible under physiological conditions (Iglewski et al., 1977) . However, resistance to PE can emerge as a result of the selection of elongation factor 2 variants which are less accessible to the toxin. Further mechanisms which might contribute to the resistance of SEN7-PE-pretreated cells include inherent differences in their ability to internalise and process the immunotoxin and cell-surface alterations that impede the passage of the toxin across the membrane (Godal et al., 1986; Goldmacher et al., 1987) . The capability of SCLC cells to modulate prominent cell-surface antigens during antibody-based immunotherapy and to acquire resistance to toxins and chemotherapeutic drugs strongly supports their high evolutionary potential. As a rationale, a combination of alternative therapeutic strategies should include immunotoxins which employ not only different toxins but also different target antigens in order to achieve maximal efficacy. Altogether, since the SCLC cells were less able to develop resistance to ricin as compared with PE, ricin seems to be a more potent cytotoxic agent in this tumour system.
In conclusion, we describe the potent and selective cytotoxic activities of immunotoxins made with the MAb SEN7, recognising a new NCAM epitope on SCLC cells. The lack of significant spontaneous endocytosis of cell surfacebound SEN7 implies that in order to make a selective and potent immunotoxin against NCAM 
